Table 1. Design and characteristic of trials included in the systematic review and meta-analysis.

Source	No. of patients	Mean age, y	Female patients (%)	Interventions	Baseline BMI (kg/m2)	Duration of follow-up (month)	Jadad score
Stephen R(1998) [21]	487	NG	85.2	Orlistat 120 mg three times daily	35.0	24	3
Lars S(1998) [22]	688	44.8	83.0	Orlistat 120 mg three times daily	36.0	12	5
James O.H(1999)[23]	363	46.2	86.0	Orlistat 120 mg three times daily	32.8	12	3
Michael H.D(1999) [24]	892	43.5	84.2	Orlistat 120 mg three times daily	36.3	24	5
N Finer(2000) [25]	218	41.4	88.5	Orlistat 120 mg three times daily	36.8	12	5
W.P.T James(2000) [26]	467	40.6	83.5	Sibutramine 10 mg daily	36.6	24	4
Alfred W(2001) [27]	606	43.4	75.4	Sibutramine15 mg daily	34.8	10	6
M Krempf(2003) [28]	696	41	86.4	Orlistat 120 mg three times daily	36.1	18	4
The S.A.T Study (2003) [29]	348	42.7	74.4	Sibutramine15 mg daily	35.4	12	6
R.I Berkowitz(2003) [35]	82	14.1	55.0	Sibutramine5 or 10 mg daily	37.8	12	6
Jarl S.T(2004) [30]	3277	43.3	55.2	Orlistat 120 mg three times daily	37.3	48	4
Julie A.P(2004) [31]	588	48.3	81.6	Sibutramine10 mg daily	37.8	12	5
A Godoy-Matos (2004) [36]	60	16.2	81.7	Sibutramine10 mg daily	36.8	6	4
Chanoine J.P(2005) [32]	539	13.6	67.0	Orlistat 120 mg three times daily	35.6	12	5
RIO-Europe Study Group(2005) [37]	1507	45.0	79.5	Rimonabant 5 or 20 mg daily	36.0	12	6
Rimonabant in Obesity–Lipids Study Group(2005) [38]	1036	47.8	60.6	Rimonabant 5 or 20 mg daily	34.0	12	6
James W.A(2006) [33]	391	46.2	94.4	Orlistat 60 mg three times daily	26.8	4	5
W.S.C Poston(2006) [34]	167	40.7	91.6	Orlistat 120 mg three times daily	36.0	12	2
L.M Garcia-Morales (2006) [39]	46	15.0	56.5	Sibutramine10 mg daily	35.9	6	5
S.R Daniels (2007) [15]	498	13.7	64.7	Sibutramine 10 mg daily	36.1	12	4
ADAGIO-Lipids Investigators(2009) [16]	803	49.6	53.6	Rimonabant 20 mg daily	36.2	12	4